New drugs to the rescue for Lundbeck

As patent expirations are taking their toll on Lundbeck’s financial numbers, sales of new drugs are slowly becoming greater than the recorded losses: “It is crucial to Lundbeck,” says the company’s CFO.

Lundbeck has recorded a growth in turnover for new products of a staggering 100 %, so these now account for 17 % of total sales, and it is this group of products that is to salvage the Danish pharmaceutical outfit from the huge losses on drugs that have gone off patent. The most important of the new medicines are Lexapro for the Japanese market and Cipralex for certain European markets.

“In this quarter we have doubled turnover of new drugs and will get 1.5 billion kroner (250 million USD) from these. When you double turnover, you are not doing too shabby. It was important to us to launch some strategic initiatives, through which we focused on new drugs in order to create a greater geographical foundation, but also a far more diversified foundation with more drugs,” says CFO Anders Götzsche.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier